相关实验视频

Updated: May 12, 2026

Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice

Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice

Published on: May 3, 2012

长效的人类PASylated勒素到达小鼠中枢神经系统,并提供了优化替代疗法的潜力

Volker Morath^1,2, Stefanie Maurer^3,4, Annette Feuchtinger⁵

¹Chair of Biological Chemistry, School of Life Sciences, Technical University of Munich, Freising 85354, Germany.

Molecular pharmaceutics

|May 7, 2025

概括

一种新型的PASylated 丁候选药物在小鼠中显示出改善的溶解性和延长的半衰期. 这种第二代瘦素有效地逆转了肥胖和相关的代谢障碍,为新的治疗选择铺平了道路.

科学领域:

生物技术是生物技术.
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

瘦素对能量恒温至关重要,但目前的治疗方法有限.
化技术为蛋白质修饰提供了对PEGylation的生物替代方案.

研究的目的:

使用PASylation技术开发和严格测试第二代人类瘦素候选药物.
评估修改后的瘦素的体外和体内疗效,药理动力学和组织分布.

主要方法:

通过将Trp100替换为Gln并将其与600残留PAS多基因融合来改造人类瘦素.
在野生类型小鼠中进行了药理动力学研究和在瘦素缺乏小鼠中进行了疗效研究.
使用光标记PAS-leptin和光片光显微镜评估组织分布.

主要成果:

修改后的人类丁呈现出高溶解性,折叠稳定性和受体刺激活性.
药理动力学研究显示,在皮下注射后,血半衰期延长了18.8±3.6小时.
在四次剂量后,PASylated丁在缺乏丁的小鼠中完全逆转了病态脂肪,过和肝硬化.
组织分布分析表明PAS-丁融合蛋白的稳定性in vivo,有证据表明PAS标签在细胞转移过程中分裂.

结论:

开发的第二代PASylated丁显示了对代谢障碍的显著治疗潜力.
这种修改后的瘦素可使剂量间隔延长,解决当前瘦素治疗的局限性.
进一步开发这种PASylated瘦素可能会导致改善治疗与瘦素缺乏症相关的疾病.

关键词:

通过PASylation进行化.这是一种阿迪波基因 (adipokine).血脑屏障是什么意思光片光显微镜光显微镜肥胖症肥胖症肥胖症肥胖症血半衰期血半衰期

更多相关视频

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

相关概念视频

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...